NCT00392834 · OUTCOME

Event-free Survival (EFS)

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma · Source last updated 2018-06-06

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 6-8 weeks post treatment, every 4 months post-treatment for 2 years

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
reporting Status: NOT_POSTED
time Frame: 6-8 weeks post treatment, every 4 months post-treatment for 2 years
title: Event-free Survival (EFS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice